Skip to main content
. 2020 Nov 2;11:536854. doi: 10.3389/fgene.2020.536854

Figure 2.

Figure 2

miR-296-5p directly targets Bcl-xl. (A) The binding site of hsa-miR-296-5p and Bcl-xl 3'-UTR predicted by Starbase software. (B) The luciferase activity of Bcl-xl in 293 T cells transfected with miR-296-5p mimic or NC mimic. (C) The expression of miR-296-5p in lymphocytes determined by RT-qPCR. (D) The mRNA expression of Bcl-xl in lymphocyte series determined by RT-qPCR. (E) The protein expression of BCL-XL normalized to GAPDH in lymphocyte series determined by Western blot assay. *p < 0.05 compared with cells transfected with NC mimic, #p < 0.05 compared with cells transfected with inhibitor NC. The results were measurement data and expressed as mean ± standard deviation, and data comparison between two groups was performed using an unpaired sample t-test. The cell experiment was repeated three times independently.